EDEN — Eden Research Share Price
Last trade - 00:00- £13.60m
- £8.84m
- £3.19m
- 20
- 24
- 23
- 10
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.07 | ||
| Price to Tang. Book | 1.93 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.46 | ||
| EV to EBITDA | 2.53 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -15.7% | ||
| Return on Equity | -17.27% | ||
| Operating Margin | -50.78% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 1.83 | 1.37 | 1.23 | 1.83 | 3.19 | 4.3 | 5 | 2.85% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Eden Research plc is a United Kingdom-based company, which is focused on biopesticides for sustainable agriculture. The Company develops and supplies biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries. Its products are formulated with terpene active ingredients, based on natural plant defense metabolites. Its product portfolio includes Mevalone and Cedroz. Mevalone is a foliar biofungicide, which targets a key disease affecting grapes and other high-value fruit and vegetable crops. Cedroz is a bionematicide that targets free-living nematodes, which are parasitic worms that affect a range of high-value fruit and vegetable crops globally. The Company's Sustaine encapsulation technology is used to harness the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease of use.
Directors
- Lykele van der Broek NEC
- Sean Smith CEO
- Alex Abrey CFO
- Michael Carroll OTH
- Aoife Dillon OTH
- Robin Cridland NID (52)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- June 22nd, 1995
- Public Since
- May 11th, 2012
- No. of Employees
- 19
- Sector
- Chemicals
- Industry
- Basic Materials
- Exchange
- London Stock Exchange
- Shares in Issue
- 533,352,523
- Address
- 67C Innovation Drive, Milton Park, OXFORD, OX14 4RQ
- Web
- https://www.edenresearch.com/
- Phone
- +44 1285359555
- Auditors
- PKF Littlejohn LLP
Latest News for EDEN
Upcoming Events for EDEN
Eden Research PLC Annual Shareholders Meeting
Half Year 2025 Eden Research PLC Earnings Release
Similar to EDEN
Atome
London Stock Exchange
Carclo
London Stock Exchange
Croda International
London Stock Exchange
Eastman Chemical Co
London Stock Exchange
Elementis
London Stock Exchange
FAQ
As of Today at 20:22 UTC, shares in Eden Research are trading at 2.55p. This share price information is delayed by 15 minutes.
Shares in Eden Research last closed at 2.55p and the price had moved by -47.42% over the past 365 days. In terms of relative price strength the Eden Research share price has underperformed the FTSE All Share Index by -49.49% over the past year.
The overall consensus recommendation for Eden Research is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreEden Research does not currently pay a dividend.
Eden Research does not currently pay a dividend.
Eden Research does not currently pay a dividend.
To buy shares in Eden Research you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 2.55p, shares in Eden Research had a market capitalisation of £13.60m.
Here are the trading details for Eden Research:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: EDEN
Based on an overall assessment of its quality, value and momentum Eden Research is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Eden Research is 20.00p. That is 684.31% above the last closing price of 2.55p.
Analysts covering Eden Research currently have a consensus Earnings Per Share (EPS) forecast of -£0.00 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Eden Research. Over the past six months, its share price has underperformed the FTSE All Share Index by -32.7%.
As of the last closing price of 2.55p, shares in Eden Research were trading -32.69% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Eden Research PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 2.55p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Eden Research's management team is headed by:
- Lykele van der Broek - NEC
- Sean Smith - CEO
- Alex Abrey - CFO
- Michael Carroll - OTH
- Aoife Dillon - OTH
- Robin Cridland - NID